Expression of CCL23 in hepatocellular carcinoma and its effect on prognosis

Abstract

Abstract: Objective To investigate the most significant chemokine of expression in hepatocellular carcinoma(HCC) and its clinical value in prognosis of HCC patients. Methods CC chemokine ligand 23(CCL23) was screened as the the most significant chemokine of expression in hepatocellular carcinoma and adjacent tissues using a public databases. Its expression was verified in HCC tissues in our hospital by quantitative polymerase chain reaction and immunohistochemistry staining. Then the correlation between the level of CCL23 and the clinicopathological characteristics, the prognosis of HCC patients was investigated. Results CCL23 was significantly downregulated in liver cancer tissues in public databases and HCC patients in our hospital(TCGA, GSE14520, GSE25097: P<0.0001, GE64041: P=0.0003, GSE57957: P=0.0001, our hospital: P<0.0001). The patients with higher level of CCL23 in tumor tissues had longer overall survival period(TCGA: P=0.0026, GSE14520: P=0.0014, our hospital: P<0.0001) and recurrence-free survival period(TCGA: P=0.0306, GSE14520: P=0.0189, our hospital: P<0.0001). Conclusion The expression of CCL23 in liver cancer tissues is significantly decreased, which may predict the prognosis of HCC patients and act as a potential target for clinical treatment.

Key words: Hepatocellular carcinoma, Public database, Chemokine, CC chemokine ligand 23, Prognosis

WANG Jian-ye, ZHAO Zhi-cong, HOU jia-jie, XIA Qiang. Expression of CCL23 in hepatocellular carcinoma and its effect on prognosis[J]. Chinese Hepatolgy, 2019, 24(4): 368-372.

References

[1] Zlotnik A, Yoshie O. Chemokines a new classification system and their role in. Immunity,2000,12:121-127.
[2] Zlotnik A, Yoshie O. The chemokine superfamily revisited. Immunity,2012,36:705-716.
[3] Youn BB-S, Zhang SM, Broxmeyer HE, et al. Characterization of CKβ8 and CKβ8-1: Two alternatively spliced forms of human β-Chemokine, chemoattractants for neutrophils, monocytes, and lymphocytes, and potent agonists at CC chemokine receptor 1. Blood,1998,91:3118-3126.
[4] Patel BVP, Kreider BL, Li Y, et al. Molecular and functional characterization of two novel human C-C chemokines as inhibitors of two distinct classes of myeloid progenitors. J Exp Med,1997,185:1163–1172.
[5] B N, DK M, GW B, et al. Dendritic cells and MPIF-1 chemotactic activity and inhibition of endogenous chemokine production by IFN-r and CD40 ligation. J Leukoc Biol,1999,65:822-828.
[6] Zhang X, Wan JX, Ke ZP, et al. TMEM88, CCL14 and CLEC3B as prognostic biomarkers for prognosis and palindromia of human hepatocellular carcinoma. Tumour Biol,2017,39:1-9.
[7] Wang Y, Bai Z, Niu Z, et al. Transcriptomic analyses of chemokines reveal that down-regulation of XCR1 is associated with advanced hepatocellular carcinoma. Biochem Biophys Res Commun,2018,496:1314-1321.
[8] Liang Z, Brooks J, Willard M, et al. CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. Biochem Biophys Res Commun,2007,359:716-722.
[9] Lin L, Han MM, Wang F, et al. CXCR7 stimulates MAPK signaling to regulate hepatocellular carcinoma progression. Cell Death Dis,2014,5:e1488.
[10] Matsubara T, Ono T, Yamanoi A, et al. Fractalkine-CX3CR1 axis regulates tumor cell cycle and deteriorates prognosis after radical resection for hepatocellular carcinoma. J Surg Oncol,2007,95:241-249.
[11] Uchida H, Iwashita Y, Sasaki A, et al. Chemokine receptor CCR6 as a prognostic factor after hepatic resection for hepatocellular carcinoma. J Gastroenterol Hepatol,2006,21:161-168.
[12] Han I-S, Ra J-S, Kim M-W, et al. Differentiation of CD34+ cells from human cord blood and murine bone marrow is suppressed by C6 b-Chemokines. Mol Cells,2003,15:176-180.
[13] Li Y, Wu J, Zhang P. CCL15/CCR1 axis is involved in hepatocellular carcinoma cells migration and invasion. Tumour Biol,2016,37:4501-4507.
[14] Yuan Y, Liu J, Liu Z, et al. Chemokine CCL3 facilitates the migration of hepatoma cells by changing the concentration intracellular Ca. Hepatol Res,2010,40:424-431.